Streetbeat News

Revenues

TXG

11 analysts have recently rated 10x Genomics (NASDAQ:TXG), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has dropped by 24.37% to $28.36. Analysts have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. Despite positive revenue growth, the company faces challenges with low ROE and ROA.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 6:01 pm

NKE

Nike (NYSE:NKE) received mixed analyst ratings with a slight positive shift in average price targets. Analysts have adjusted their ratings and price targets based on recent market conditions and company performance. Despite a decline in revenue growth, Nike maintains strong financial metrics such as net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 6:00 pm

SIGI

Analysts have provided mixed reviews for Selective Insurance Group (NASDAQ:SIGI) over the past three months, with a recent decrease in the average 12-month price target. The company's financial metrics show strong revenue growth but challenges in profitability and returns.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 6:00 pm

GSK

IQV

PFE

GSK and Pfizer face declining sales of their RSV vaccines due to narrowed age recommendations by the CDC, impacting demand significantly. The vaccines are now recommended for adults aged 75 and above, and those aged 60-74 with certain chronic conditions. This has led to a drop in demand, with pharmacists reporting a two-thirds decrease compared to last year. GSK and Pfizer are relying on RSV vaccines to build new revenue streams as they face generic competition for their top-selling drugs.

Portfolio Pulse from Vandana Singh

October 10, 2024 | 6:00 pm

Parker Hannifin (NYSE:PH) has outperformed the market over the past 20 years, achieving an average annual return of 14.02%. A $1000 investment in PH 20 years ago would now be worth $14,911.95. The article highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 6:00 pm

MRK

MRNA

MYNZ

PFE

Pharmaceutical companies are focusing on personalized cancer therapies and immunotherapy as new strategies against cancer. Pfizer and Moderna are investing in mRNA technology for cancer treatment, while Merck has shown success with its Keytruda treatment. Mainz Biomed is advancing early cancer detection with its ColoAlert test.

Portfolio Pulse from Upwallstreet

October 10, 2024 | 6:00 pm

NVO

Analysts have provided mixed ratings for Novo Nordisk (NYSE:NVO) over the past three months, with a consistent 'Somewhat Bullish' sentiment. The average 12-month price target is $160, slightly down from the previous $161.43. Novo Nordisk shows strong financial performance with significant revenue growth and high net margins.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 6:00 pm

LNG

Cheniere Energy (NYSE:LNG) has significantly outperformed the market over the past 15 years, with an annualized return of 32.6%. A $1000 investment in LNG 15 years ago would now be worth $72,011.24. The article highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 6:00 pm

DHI

ITB

LEN

PHM

TMHC

Hurricane Milton's impact on Florida could delay new home construction, affecting major homebuilders like Taylor Morrison, PulteGroup, Lennar, and D.R. Horton. This may lead to increased costs and conservative outlooks in upcoming earnings reports. The iShares U.S. Home Construction ETF, which holds these stocks, could also be impacted.

Portfolio Pulse from Chris Katje

October 10, 2024 | 6:00 pm

AMX

ICARO Media Group has signed a 10-year contract with Claro Brasil, a subsidiary of América Móvil, to enhance Claro's advertising revenue through digital platforms. This partnership involves leveraging RioVerde's communication innovations.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 5:35 pm